Find a Drug
Advanced Search

Professional

DepoCyt

Clinical Pharmacology
font size

Clinical Pharmacology

The second study was a randomized, multi-center, multi-arm study involving a total of 124 treated patients with either solid tumors or lymphomas. In this study, 24 patients with lymphoma were randomized and treated with DepoCyt or cytarabine, Patients received 6 two-week induction cycles of DepoCyt 50 mg every 2 weeks or cytarabine 50 mg twice weekly. Patients then received four maintenance cycles of DepoCyt 50 mg every 4 weeks, or cytarabine 50 mg weekly for 4 weeks. In both studies, patients received concurrent treatment with dexamethasone to minimize symptoms associated with chemical arachnoiditis (see WARNINGS and DOSAGE AND ADMINISTRATION). In this study, cytological response was assessed in a blinded fashion utilizing a similar definition as in the first study. The results in patients with lymphomatous meningitis are shown in Table 1.

Table 1: Complete Cytological Responses in Patients with Lymphomatous Meningitis


  DepoCyt® Cytarabine
Study 1 7/17 (41%) 1/16 (6%)
95% CI (18%, 67%) (0%, 30%)
Study 2 4/12 (33%) 2/12 (17%)
95% CI (10%, 65%) (2%, 48%)
Brand Name: DepoCyt
Generic Name: Cytarabine Liposome Injection
Bookmark this page:

Cancer

Get the latest treatment options.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn

Cancer and ExerciseCancer and Exercise
Resting to conserve energy may not be the best remedy for fatigue during radiation therapy. See more WebMD Videos »